Coltuximab ravtansine (SAR3419) is an antibody-drug conjugate (ADC) targeting CD19 created by conjugating a derivative of the potent microtubule-acting cytotoxic agent, maytansine, to a version of the anti-CD19 antibody, anti-B4, that was humanized as an IgG1 by variable domain resurfacing. Four different linker-maytansinoid constructs were synthesized (average ∼3.5 maytansinoids/antibody for each) to evaluate the impact of linker-payload design on the activity of the maytansinoid-ADCs targeting CD19. Anti-CD19 humanized monoclonal antibody conjugated to DM4.
Research Grade Coltuximab
Overview
Catalog No.
HB996016
Host species
Chimeric
Species reactivity
Human
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Purity
>95% as determined by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1-kappa
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
Purification
Protein A/G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
Mammalian Cells
Accession
P15391
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative name
SAR3419, 1269764-99-9
Species
Human
Note
For research use only. Not suitable for clinical or therapeutic use.
Description
Images
Bioactivity
SEC-HPLC detection for Research Grade Coltuximab.
SDS-PAGE
SDS-PAGE for Research Grade Coltuximab.